Forma Therapeutics' Olutasidenib Achieves 33% Remission Rate In Acute Myeloid Leukemia Patients

Comments
Loading...
  • Forma Therapeutics Holdings Inc FMTX announced interim data from its Phase 2 trial of olutasidenib in relapsed/refractory acute myeloid leukemia (R/R AML).
  • The data will be presented at the upcoming 2021 American Society of Clinical Oncology Annual Meeting.
  • Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in R/R AML patients with the IDH1 mutation.
  • The CR rate was 30% (37/123) and the CR with partial hematologic recovery (CRh) rate was 3% (4/123).
  • The duration of the response of 13.8 months is the longest reported in this treatment setting to date.
  • The median overall survival (OS) was 10.5 months. The median OS for non-CR/CRh responders was 15.0 months.
  • Among those with CR/CRh, the estimated 18-month survival is 87%; median overall survival has not yet been reached.
  • A favorable tolerability profile was observed following continuous oral treatment with olutasidenib 150mg twice daily.
  • Price Action: FMTX shares are up 2.2% at $28.42 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!